Literature DB >> 16827663

Design of immunogens that present the crown of the HIV-1 V3 loop in a conformation competent to generate 447-52D-like antibodies.

Kausik Chakraborty1, Venuka Durani, Edward Roshan Miranda, Michael Citron, Xiaoping Liang, William Schleif, Joseph G Joyce, Raghavan Varadarajan.   

Abstract

gp120 is a subunit of the envelope glycoprotein of HIV-1. The third variable loop region of gp120 (V3 loop) contains multiple immunodominant epitopes and is also functionally important for deciding cell-tropism of the virus. 447-52D is a monoclonal antibody that recognizes the conserved tip of the V3 loop in a beta-turn conformation. This antibody has previously been shown to neutralize diverse strains of the virus. In an attempt to generate an immunogen competent to generate 447-52D-like antibodies, the known epitope of 447-52D was inserted at three different surface loop locations in the small, stable protein Escherichia coli Trx (thioredoxin). At one of the three locations (between residues 74 and 75), the insertion was tolerated, the resulting protein was stable and soluble, and bound 447-52D with an affinity similar to that of intact gp120. Upon immunization, the V3 peptide-inserted Trx scaffold was able to generate anti-V3 antibodies that could compete out 447-52D binding to gp120. Epitope mapping studies demonstrated that these anti-V3 antibodies recognized the same epitope as 447-52D. Although the 447-52D-type antibodies were estimated to be present at concentrations of 50-400 microg/ml of serum, these were not able to effect neutralization of strains like JRFL and BAL but could neutralize the sensitive MN strain. The data suggest that because of the low accessibility of the V3 loop on primary isolates such as JRFL, it will be difficult to elicit a V3-specific, 447-52D-like antibody response to effectively neutralize such isolates.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16827663      PMCID: PMC1615908          DOI: 10.1042/BJ20060588

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  53 in total

1.  Structural rationale for the broad neutralization of HIV-1 by human monoclonal antibody 447-52D.

Authors:  Robyn L Stanfield; Miroslaw K Gorny; Constance Williams; Susan Zolla-Pazner; Ian A Wilson
Journal:  Structure       Date:  2004-02       Impact factor: 5.006

2.  Structure of a V3-containing HIV-1 gp120 core.

Authors:  Chih-chin Huang; Min Tang; Mei-Yun Zhang; Shahzad Majeed; Elizabeth Montabana; Robyn L Stanfield; Dimiter S Dimitrov; Bette Korber; Joseph Sodroski; Ian A Wilson; Richard Wyatt; Peter D Kwong
Journal:  Science       Date:  2005-11-11       Impact factor: 47.728

3.  Complete nucleotide sequences of functional clones of the AIDS virus.

Authors:  L Ratner; A Fisher; L L Jagodzinski; H Mitsuya; R S Liou; R C Gallo; F Wong-Staal
Journal:  AIDS Res Hum Retroviruses       Date:  1987       Impact factor: 2.205

4.  Polyvalent human immunodeficiency virus synthetic immunogen comprised of envelope gp120 T helper cell sites and B cell neutralization epitopes.

Authors:  T J Palker; T J Matthews; A Langlois; M E Tanner; M E Martin; R M Scearce; J E Kim; J A Berzofsky; D P Bolognesi; B F Haynes
Journal:  J Immunol       Date:  1989-05-15       Impact factor: 5.422

5.  Reconstitution of Escherichia coli thioredoxin from complementing peptide fragments obtained by cleavage at methionine-37 or arginine-73.

Authors:  I Slaby; A Holmgren
Journal:  J Biol Chem       Date:  1975-02-25       Impact factor: 5.157

6.  Thermodynamic characterization of monomeric and dimeric forms of CcdB (controller of cell division or death B protein).

Authors:  Kanika Bajaj; Ghadiyaram Chakshusmathi; Kiran Bachhawat-Sikder; Avadhesha Surolia; Raghavan Varadarajan
Journal:  Biochem J       Date:  2004-06-01       Impact factor: 3.857

7.  Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein.

Authors:  K Javaherian; A J Langlois; C McDanal; K L Ross; L I Eckler; C L Jellis; A T Profy; J R Rusche; D P Bolognesi; S D Putney
Journal:  Proc Natl Acad Sci U S A       Date:  1989-09       Impact factor: 11.205

8.  Structure and enzymatic functions of thioredoxin refolded by complementation of two tryptic peptide fragments.

Authors:  I Slabý; A Holmgren
Journal:  Biochemistry       Date:  1979-12-11       Impact factor: 3.162

9.  Type-specific neutralization of the human immunodeficiency virus with antibodies to env-encoded synthetic peptides.

Authors:  T J Palker; M E Clark; A J Langlois; T J Matthews; K J Weinhold; R R Randall; D P Bolognesi; B F Haynes
Journal:  Proc Natl Acad Sci U S A       Date:  1988-03       Impact factor: 11.205

10.  Antibodies that inhibit fusion of human immunodeficiency virus-infected cells bind a 24-amino acid sequence of the viral envelope, gp120.

Authors:  J R Rusche; K Javaherian; C McDanal; J Petro; D L Lynn; R Grimaila; A Langlois; R C Gallo; L O Arthur; P J Fischinger
Journal:  Proc Natl Acad Sci U S A       Date:  1988-05       Impact factor: 11.205

View more
  14 in total

1.  Neutralizing and other antiviral antibodies in HIV-1 infection and vaccination.

Authors:  David C Montefiori; Lynn Morris; Guido Ferrari; John R Mascola
Journal:  Curr Opin HIV AIDS       Date:  2007-05       Impact factor: 4.283

2.  An optimally constrained V3 peptide is a better immunogen than its linear homolog or HIV-1 gp120.

Authors:  Adi Moseri; Subramanyam Tantry; Yael Sagi; Boris Arshava; Fred Naider; Jacob Anglister
Journal:  Virology       Date:  2010-03-26       Impact factor: 3.616

3.  Modification of one epitope-flanking amino acid allows for the induction of friend retrovirus-specific CD8+ T cells by Adenovirus-based immunization.

Authors:  Philipp Gödel; Sonja Windmann; Kirsten K Dietze; Ulf Dittmer; Wibke Bayer
Journal:  J Virol       Date:  2012-08-29       Impact factor: 5.103

4.  Expression, glycoform characterization, and antibody-binding of HIV-1 V3 glycopeptide domain fused with human IgG1-Fc.

Authors:  Qiang Yang; Cishan Li; Yadong Wei; Wei Huang; Lai-Xi Wang
Journal:  Bioconjug Chem       Date:  2010-05-19       Impact factor: 4.774

5.  Engineering, expression, purification, and characterization of stable clade A/B recombinant soluble heterotrimeric gp140 proteins.

Authors:  George Sellhorn; Zane Kraft; Zachary Caldwell; Katharine Ellingson; Christine Mineart; Michael S Seaman; David C Montefiori; Eliza Lagerquist; Leonidas Stamatatos
Journal:  J Virol       Date:  2011-10-26       Impact factor: 5.103

Review 6.  Protein engineering strategies for the development of viral vaccines and immunotherapeutics.

Authors:  Jayne F Koellhoffer; Chelsea D Higgins; Jonathan R Lai
Journal:  FEBS Lett       Date:  2013-10-21       Impact factor: 4.124

7.  Neutralizing activity of antibodies to the V3 loop region of HIV-1 gp120 relative to their epitope fine specificity.

Authors:  Ralph Pantophlet; Terri Wrin; Lisa A Cavacini; James E Robinson; Dennis R Burton
Journal:  Virology       Date:  2008-09-26       Impact factor: 3.616

8.  Mimicking the structure of the V3 epitope bound to HIV-1 neutralizing antibodies.

Authors:  Amit Mor; Eugenia Segal; Brenda Mester; Boris Arshava; Osnat Rosen; Fa-Xiang Ding; Joseph Russo; Amnon Dafni; Fabian Schvartzman; Tali Scherf; Fred Naider; Jacob Anglister
Journal:  Biochemistry       Date:  2009-04-21       Impact factor: 3.162

9.  An oligosaccharide-based HIV-1 2G12 mimotope vaccine induces carbohydrate-specific antibodies that fail to neutralize HIV-1 virions.

Authors:  Joseph G Joyce; Isaac J Krauss; Hong C Song; David W Opalka; Karen M Grimm; Deborah D Nahas; Mark T Esser; Renee Hrin; Meizhen Feng; Vadim Y Dudkin; Michael Chastain; John W Shiver; Samuel J Danishefsky
Journal:  Proc Natl Acad Sci U S A       Date:  2008-10-06       Impact factor: 11.205

10.  HIV p24 as scaffold for presenting conformational HIV Env antigens.

Authors:  Maria Tagliamonte; Daniela Marasco; Alessia Ruggiero; Angelo De Stradis; Maria Lina Tornesello; Maxim Totrov; Franco Maria Buonaguro; Luigi Buonaguro
Journal:  PLoS One       Date:  2012-08-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.